NAFTA 2.0: Obstacles to More Affordable Medicines
NAFTA 2.0 (USMCA) will keep drug prices out of reach for American patients.
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients.
The U.S.-Mexico-Canada Agreement (USMCA), the update to the North America Free Trade Agreement (NAFTA), contains provisions that will: